Heron Therapeutics’ (HRTX) “Buy” Rating Reaffirmed at Oppenheimer Holdings, Inc.
Oppenheimer Holdings, Inc. reissued their buy rating on shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) in a report released on Friday morning. The brokerage currently has a $27.00 price objective on the biotechnology company’s stock. Oppenheimer Holdings also issued estimates for Heron Therapeutics’ FY2020 earnings at $1.45 EPS and FY2021 earnings at $3.29 EPS.
HRTX has been the subject of a number of other research reports. Mizuho reaffirmed a buy rating and issued a $28.00 price target on shares of Heron Therapeutics in a report on Tuesday, November 7th. Cantor Fitzgerald set a $31.00 price target on shares of Heron Therapeutics and gave the company a buy rating in a report on Friday, October 20th. Cowen and Company reaffirmed a buy rating and issued a $40.00 price target on shares of Heron Therapeutics in a report on Monday, November 6th. BidaskClub raised shares of Heron Therapeutics from a sell rating to a hold rating in a report on Saturday, August 26th. Finally, Jefferies Group LLC reaffirmed a buy rating and issued a $26.00 price target on shares of Heron Therapeutics in a report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. Heron Therapeutics currently has an average rating of Buy and a consensus target price of $28.36.
Shares of Heron Therapeutics (NASDAQ HRTX) traded down $0.55 during trading hours on Friday, hitting $15.80. 883,400 shares of the company were exchanged, compared to its average volume of 818,124. The company has a quick ratio of 2.02, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. Heron Therapeutics has a 1 year low of $12.21 and a 1 year high of $20.85.
Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The firm had revenue of $8.57 million during the quarter, compared to the consensus estimate of $8.12 million. sell-side analysts forecast that Heron Therapeutics will post -3.42 earnings per share for the current year.
Institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC purchased a new stake in Heron Therapeutics in the 2nd quarter worth about $78,134,000. Virtu KCG Holdings LLC raised its position in Heron Therapeutics by 62.5% in the 2nd quarter. Virtu KCG Holdings LLC now owns 25,053 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 9,637 shares during the period. Bank of New York Mellon Corp raised its position in Heron Therapeutics by 7.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 204,857 shares of the biotechnology company’s stock worth $2,837,000 after purchasing an additional 14,086 shares during the period. Teachers Advisors LLC raised its position in Heron Therapeutics by 20.5% in the 1st quarter. Teachers Advisors LLC now owns 69,720 shares of the biotechnology company’s stock worth $1,046,000 after purchasing an additional 11,862 shares during the period. Finally, Royce & Associates LP purchased a new stake in Heron Therapeutics in the 2nd quarter worth about $796,000.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.